Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Laboratory parameters for the MS, sarcopenia, and combined groups compared with the control group are presented in Table 2.Laboratory test data by groupVariablesControl (n = 174)MS (n = 122)PaSarcopenia (n = 89)PbCombined (n = 75)PcBMD (g/cm3)0.67 (0.57, 0.77)0.67 (0.57, 0.78)0.70.65 (0.56, 0.74)0.40.59 (0.52, 0.74)0.019VitD (ng/mL)55 (44, 73)52 (39, 61)0.00254 (41, 64)0.04951 (40, 66)0.014WBC (10^9/L)8.28 (6.74, 10.28)9.18 (7.33, 11.52)0.0078.83 (7.09, 10.40)0.49.07 (7.52, 11.76)0.013NE (10^9/L)6.32 (5.09, 8.12)7.31 (5.34, 9.28)0.0127.12 (5.47, 8.47)0.0827.39 (5.75, 10.27)0.002LYM (10^9/L)1.10 (0.85, 1.43)1.16 (0.89, 1.47)0.30.90 (0.69, 1.17) < 0.0011.03 (0.79, 1.33)0.084Hb (g/L)107 ± 18110 ± 190.089105 ± 190.4106 ± 19 > 0.9Plt (10^9/L)178 (145, 227)199 (158, 262)0.029188 (152, 261)0.3194 (159, 233)0.2TP (g/L)63.7 ± 6.264.9 ± 5.40.1063 ± 70.564.3 ± 6.50.5ALB (g/L)34.7 (32.2, 37.0)34.7 (32.7, 37.3)0.433.9 (31.0, 36.6)0.234.9 (31.7, 36.8) > 0.9TG (mmol/L)1.12 (0.86, 1.47)1.78 (1.19, 2.10) < 0.0010.95 (0.74, 1.31)0.0081.71 (1.12, 1.99) < 0.001HDL-C (mmol/L)1.08 (0.87, 1.28)0.89 (0.78, 1.05) < 0.0011.06 (0.87, 1.27) > 0.90.94 (0.86, 1.12)0.027BMD Bone Mineral Density; VitD Vitamin D; WBC White Blood Cell; NE Neutrophils; LYM Lymphocytes; Hb Hemoglobin; Plt Platelets; TP total protein; ALB Albumin; TG Triglycerides; HDL-C High-Density Lipoprotein CholesterolaBetween Control and MS groupsbBetween Control and Sarcopenia groupscBetween Control and Combined groups
Source: Preoperative and postoperative laboratory parameters. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Following these criteria, a final cohort of 460 patients was selected for analysis (Fig.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Effect of sarcopenia combined with Metabolic Syndrome (MS) on the prognosis of intertrochanteric fractures: a retrospective clinical study
Study design awaiting verification · BMC Musculoskeletal Disorders · 2025
Original publication title
Effect of sarcopenia combined with Metabolic Syndrome (MS) on the prognosis of intertrochanteric fractures: a retrospective clinical study
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Intertrochanteric fractures pose significant health risks for elderly patients. While metabolic syndrome (MS) and sarcopenia independently impact postoperative outcomes, their synergistic effects on intertrochanteric fracture prognosis remain unclear. This study investigates the individual and combined influence of MS and sarcopenia on complications and functional recovery in elderly patients with intertrochanteric fractures.
Source: BackgroundAbstract: What methods does the paper describe?
We retrospectively analyzed 460 elderly patients with intertrochanteric fractures, categorized into four groups: control (n = 174), MS (n = 122), sarcopenia (n = 89), and combined (n = 75). Preoperative: perioperative and postoperative data of the MS, sarcopenia, and combined groups were compared with the control group. Primary outcomes included 3-month Barthel Index (BI) and Harris Hip Score (HHS). Multivariate logistic regression identified predictors of poor recovery (HHS < 70).
Source: MethodsAbstract: Results
The MS group had younger patients with higher body mass index (BMI), hypertension, diabetes prevalence, and longer surgery durations (P < 0.05). Sarcopenia and combined groups exhibited lower weight, BMI, handgrip strength (HS), appendicular skeletal muscle mass index (ASMI), and higher American society of Aneshesiologists (ASA) scores (P < 0.05). The MS, sarcopenia, and combined groups had higher incidences of pulmonary infections and pressure ulcers compared with the control group (P < 0.05). The sarcopenia and combined groups also had higher rates of organ failure (P < 0.05), with the combined group showing increased ICU admission (P = 0.003) and in-hospital mortality (P = 0.027).
At three months post-discharge, the sarcopenia and combined groups exhibited higher mortality rates (P < 0.001). At the 3-month follow-up, the sarcopenia and combined groups had significantly lower HHS and BI compared to the control group (P < 0.05). Multivariate logistic regression identified sarcopenia alone (OR 6.50, 95% CI 2.56 to 20.10; P < 0.001) and combined with MS (OR 9.46, 95% CI 3.33 to 34.80; P < 0.001) as significant predictors of poor postoperative recovery.
Source: ResultsAbstract: Conclusion
Sarcopenia significantly worsens postoperative prognosis in elderly intertrochanteric fracture patients, with synergistic deterioration when combined with MS. Chronic inflammation, insulin resistance, and muscle-bone metabolic dysregulation drive adverse outcomes. Comprehensive preoperative screening for sarcopenia and MS, coupled with tailored nutritional support and early rehabilitation, is critical to mitigate complications and improve functional recovery. These findings advocate for integrated care protocols targeting metabolic-musculoskeletal health in geriatric fracture management.
Source: ConclusionAuthors’ abstract
Background
Intertrochanteric fractures pose significant health risks for elderly patients. While metabolic syndrome (MS) and sarcopenia independently impact postoperative outcomes, their synergistic effects on intertrochanteric fracture prognosis remain unclear. This study investigates the individual and combined influence of MS and sarcopenia on complications and functional recovery in elderly patients with intertrochanteric fractures.
Methods
We retrospectively analyzed 460 elderly patients with intertrochanteric fractures, categorized into four groups: control (n = 174), MS (n = 122), sarcopenia (n = 89), and combined (n = 75). Preoperative: perioperative and postoperative data of the MS, sarcopenia, and combined groups were compared with the control group. Primary outcomes included 3-month Barthel Index (BI) and Harris Hip Score (HHS). Multivariate logistic regression identified predictors of poor recovery (HHS < 70).
Results
The MS group had younger patients with higher body mass index (BMI), hypertension, diabetes prevalence, and longer surgery durations (P < 0.05). Sarcopenia and combined groups exhibited lower weight, BMI, handgrip strength (HS), appendicular skeletal muscle mass index (ASMI), and higher American society of Aneshesiologists (ASA) scores (P < 0.05). The MS, sarcopenia, and combined groups had higher incidences of pulmonary infections and pressure ulcers compared with the control group (P < 0.05). The sarcopenia and combined groups also had higher rates of organ failure (P < 0.05), with the combined group showing increased ICU admission (P = 0.003) and in-hospital mortality (P = 0.027).
At three months post-discharge, the sarcopenia and combined groups exhibited higher mortality rates (P < 0.001). At the 3-month follow-up, the sarcopenia and combined groups had significantly lower HHS and BI compared to the control group (P < 0.05). Multivariate logistic regression identified sarcopenia alone (OR 6.50, 95% CI 2.56 to 20.10; P < 0.001) and combined with MS (OR 9.46, 95% CI 3.33 to 34.80; P < 0.001) as significant predictors of poor postoperative recovery.
Conclusion
Sarcopenia significantly worsens postoperative prognosis in elderly intertrochanteric fracture patients, with synergistic deterioration when combined with MS. Chronic inflammation, insulin resistance, and muscle-bone metabolic dysregulation drive adverse outcomes. Comprehensive preoperative screening for sarcopenia and MS, coupled with tailored nutritional support and early rehabilitation, is critical to mitigate complications and improve functional recovery. These findings advocate for integrated care protocols targeting metabolic-musculoskeletal health in geriatric fracture management.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12891-025-08931-2.
Publication and source details
Original title: Effect of sarcopenia combined with Metabolic Syndrome (MS) on the prognosis of intertrochanteric fractures: a retrospective clinical study
Cheng Zhang; Ding Wang; Xitao Wu; Qinrui Zhang; Lei Chen; Junzhe Lang; Congcong Wu
BMC Musculoskeletal Disorders · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Science and Technology Program of WenzhouY20210435Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T03:49:58.028887+00:00
DOI: 10.1186/s12891-025-08931-2 · PMC12305992